シェラ性抗凝固剤は,血ドキシサイクリン測定量を低下させる:ドキシPEPモニタリングへの影響
Michele B Daly1, Micah Spandau2, Tiancheng E Edwards1
1Laboratory Branch, Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA , USA.
Expert review of clinical pharmacology
|February 17, 2026
まとめ
シトラートやEDTAのようなケラート抗凝固剤は,ドキシサイクリンの血濃度を著しく低下させます. 薬物の正確な測定のために,非ケラ化抗凝固剤を使用するか,ケラ化剤に調整してください.
科学分野:
- 薬理学 薬理学とは
- 臨床化学 臨床化学について
背景:
- ドキシサイクリンの暴露後の予防は,性感染症のリスクが高い男性と性交する男性に推奨されます.
- この予防戦略の遵守と有効性を評価するために,ドキシサイクリンの正確な測定は極めて重要です.
研究 の 目的:
- 血ドキシサイクリン濃度に対する異なる抗凝固剤の影響を調査する.
- 臨床試験におけるドキシサイクリンの正確な定量化のための最適な採血方法を決定する.
主な方法:
- 参加者は200mgのドキシサイクリンを投与され,血液はシトラートまたはヘパリン管で採取されました.
- エクスビヴォ実験では,血中のドキシサイクリン濃度と比較し,薬剤を添加し,シトラート/ヘパリンまたはEDTA/ヘパリンで収集した.
- プラズマドキシサイクリンは,液体染色体-タンデム質量スペクトロメトリを用いて定量化されました.
主要な成果:
- プラズマドキシサイクリンAUCは,ヘパリン投与後の血液と比較して,シトラート血では3倍低かった.
- エクスビボ試験では,シトラートおよびEDTAの血液におけるドキシサイクリン濃度がヘパリン血液と比較して有意に低下したことが示された (p < 0.0002).
結論:
- ケラート抗凝固剤 (シトラート,EDTA) は,ドキシサイクリンの血濃度を大幅に低下させ,薬-金属イオン複合体を破壊し,赤血球の分割を増加させる可能性が高い.
- 薬理学的研究は,ドキシサイクリンの分析のためにケラ化剤を使用する場合,非ケラ化剤の抗凝固剤を優先するか,または補正因子を適用する必要があります.
関連する概念動画
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Therapeutic Drug Monitoring: Affecting Factors
258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258
Pharmacokinetics: Drug–Drug Interactions
497
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
497
Therapeutic Drug Monitoring: Drug Analysis Methods
223
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
223
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Therapeutic Drug Monitoring: Overview and Classification
388
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
388


